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Background: There is a great variability in licit prescription drug use in the population and among patients. Factors
other than purely medical ones have proven to be of importance for the prescribing of licit drugs. For example,
individuals with a high age, female gender and low socioeconomic status are more likely to use licit prescription
drugs. However, these results have not been adjusted for multi-morbidity level. In this study we investigate the
odds of using licit prescription drugs among individuals in the population and the rate of licit prescription drug use
among patients depending on gender, age and socioeconomic status after adjustment for multi-morbidity level.
Methods: The study was carried out on the total population aged 20 years or older in Östergötland county with
about 400 000 inhabitants in year 2006. The Johns Hopkins ACG Case-mix was used as a proxy for the individual
level of multi-morbidity in the population to which we have related the odds ratio for individuals and incidence
rate ratio (IRR) for patients of using licit prescription drugs, defined daily doses (DDDs) and total costs of licit
prescription drugs after adjusting for age, gender and socioeconomic factors (educational and income level).
Results: After adjustment for multi-morbidity level male individuals had less than half the odds of using licit
prescription drugs (OR 0.41 (95% CI 0.40-0.42)) compared to female individuals. Among the patients, males had
higher total costs (IRR 1.14 (95% CI 1.13-1.15)). Individuals above 80 years had nine times the odds of using licit
prescription drugs (OR 9.09 (95% CI 8.33-10.00)) despite adjustment for multi-morbidity. Patients in the highest
education and income level had the lowest DDDs (IRR 0.78 (95% CI 0.76-0.80), IRR 0.73 (95% CI 0.71-0.74)) after
adjustment for multi-morbidity level.
Conclusions: This paper shows that there is a great variability in licit prescription drug use associated with gender,
age and socioeconomic status, which is not dependent on level of multi-morbidity.
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Prescription of licit drugs is one of the most frequently
used methods to prevent and treat diseases in health
care [1]. Due to the high costs and potential risks asso-
ciated with inappropriate licit prescription drug utilization
it is of importance that drugs are prescribed in a correct
and responsible way [2]. The Swedish population of eld-
erly is increasing [3] and the prevalence of chronic dis-
ease increases with age, thus also increasing the number
of elderly patients with one or more licit prescription
drugs [2]. The licit prescription drug costs in Sweden
have escalated during the past years [4]. Due to new and
improved licit prescription drugs more medical condi-
tions can be treated. New licit prescription drugs are
developed and continuously released onto the market
and older ones get new indications. This contributes to
the increase in licit prescription drug use and costs for
licit prescription drugs. It also increases the risk of poly-
pharmacy (defined as the use of five or more daily pre-
scribed drugs), which can cause interactions, adverse
drug reactions and lead to an increased number of hos-
pital admissions [5-7]. In 2007 the licit prescription drug
costs amounted to SEK 32.8 billion (1 Swedish crown
(SEK) 0.1 Euro) [4]. Factors other than purely medical
ones are of importance for licit prescription drug use.
Women are more likely to use licit prescription drugs
and the total costs of licit prescription drug use in
women are higher than in men [2,8-10], while men have
a higher cost per dose [1,11,12]. Individuals from lower
social class have a higher usage of licit prescription drugs,
but at the same time the cost per dose is in comparison
the lowest [11-13].
The prevalence of chronic illness increases with age,
and therefore age increases the risk of receiving licit pre-
scription drug treatment. This is illustrated by the fact
that the elderly (≥65 years) in Sweden constituted 18%
of the total population during 2007 [14], but they
accounted for 41% of the total licit prescription drug
costs [15]. Our aim was to investigate the odds of using
licit prescription drugs among individuals in the popula-
tion and the rate of licit prescription drug use among
patients depending on age, gender and socioeconomic
status after adjusting for multi-morbidity level. Only a
few studies have taken the individual patient’s multi-
morbidity level into account when studying what influ-
ences licit prescription drug use [8,13]. Neither one of
these studies have taken all the patient’s diagnoses into
account when calculating the level of multi-morbidity.
We used the Johns Hopkins ACG Case-Mix System to
calculate the level of multi-morbidity. The ACG Case-
Mix system is based on a theory that multi-morbidity
corresponds to a certain need of health care resources.
The multi-morbidity is measured by analysing all diag-
noses recorded during a time period using an ACGCase-Mix algorithm. This algorithm assigns each indi-
vidual with an ACG index. This index is categorized into
six Resource Utilization Bands (RUB) or multi-morbidity
levels [16,17].
Methods
Study population
The study was carried out during 2006 on the total popu-
lation aged 20 years or older in Östergötland county with
about 400 000 inhabitants. Östergötland county is situ-
ated about 200 km southwest of Stockholm. The age
demography in Östergötland is similar to that of the rest
of Sweden [18]. Data on the population’s age, gender,
diagnoses in primary health care (PHC) and secondary
care were obtained through the Care Data Warehouse in
Östergötland (CDWÖ). Information on this register
has been described earlier [19]. The data in this regis-
ter contained information from both private and public
caregivers. The study was approved by the research
ethics committee at Linköping University (Dnr 147/05
and 29/06).
Dependent variables
Information on the use of licit prescription drugs on the
individual level was obtained through the Swedish Pre-
scribed Drug Register at the National Board of Health
and Welfare, which collects information from the Na-
tional Corporation of Swedish Pharmacies (Apoteket
AB), which at the time of the study had a monopoly on
sales of licit prescribed drugs. All the licit prescribed
drugs were tracked through Apoteket AB for the time
being. Two dependent variables were used in this study:
1. Use of licit prescription drugs in Defined Daily Doses
(DDDs) during 2006. 2. Total costs of licit prescription
drug use (Apoteket AB sales price to customers (AUP))
during 2006 in SEKs (1 Swedish crown (SEK) 0.1 Euro).
DDDs are defined by WHO as a statistical measure of
licit prescribed drug consumption and is not to be con-
fused with the number of doses prescribed by the physi-
cians. DDDs are used to standardize the comparison of
licit prescription drug use between different licit pre-
scription drugs [20]. In this study we have used the col-
lected DDDs for each patient. Over the counter drugs are
not included in this study. AUP is the sales price used by
the pharmacies when selling licit prescription drugs. It is
determined by the Dental and Pharmaceutical Benefits
Agency [21].
Independent variables
Multi-morbidity
Multi-morbidity was calculated using the Johns Hopkins
ACG Case-Mix System. The ACG Case-Mix system is
based on the theory that multi-morbidity corresponds to
a certain need of health care resources. The multi-
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during a defined period of time. The ACG Case-Mix sys-
tem has previously been described [16,17,22,23]. Indivi-
duals without need of health care according to the ACG
Case-Mix system are placed in Resource Utilization Band
0 (RUB 0) and individuals with a very high degree of need
for health care resources are placed in RUB 5. For ex-
ample, preventive interventions correspond to RUB 1, a
single chronic diagnosis could correspond to RUB 3 and
a certain combination of chronic diagnoses corresponds
to RUB 4 or RUB 5. All diagnoses from primary and sec-
ondary care from 2006 were obtained through the Care
Data Warehouse in Östergötland (CDWÖ) [19].
Socioeconomics
There are many different variables to describe socioeco-
nomics, e.g. income, education, environment and occu-
pation [24-26]. We used income and education, two
commonly used variables to describe socioeconomics,
and they have been shown not to be interchangeable
[26]. The education variable was divided into four levels:
1. Primary school not completed (<9 years). 2. Primary
school completed (9–10 years) 3. Secondary school (10-
12 years) 4. Higher education (>12 years). The dispos-
able income was divided into quartiles from the highest
to the lowest with equal number of individuals in each
quartile. For a professional career the number of years in
school is not as important as having a formal degree.
Consequently, whether or not an individual has com-
pleted primary school has great impact on professional
life and possible social position, even if there is only one
school year’s difference [26]. The information on individ-
ual level of education and income was obtained from
Statistics Sweden [27]. Due to the fact that young people
under 20 years of age had no complete record of educa-
tion and no or low income, this group was excluded
from the study. The information on educational level
was also to a high degree missing in people 70 years or
older and therefore this group was excluded when the
effect of educational level was analysed.
Statistical analysis
In this study we used STATA version 10 (Stata Corpor-
ation, Texas, USA) for statistical analyses. A descriptive
analysis was performed on the use of licit prescription
drugs in the population. The categorical variables were
compared using chi-square test. Due to the high number
in the population not using licit prescription drugs Pois-
son regression analysis was not considered valid. The
best statistical analysis that could model our data was
considered to be zero inflated negative binomial regres-
sion, which performs two simultaneous analyses [28].
One analysis is similar to logistic regression and answers
the question on what the odds are of belonging to theindividuals in the population without licit prescription
drug use and also gives an odds ratio (OR). These odds
ratios were then inverted to show odds ratio of using
licit prescription drugs. The other analysis is similar to
Poisson regression and answers the question of what the
effect is of increasing the independent variable by one
unit among patients (those that use licit prescription
drugs) and gives an incidence rate ratio (IRR). This pro-
vided two different analyses of licit prescription drug use
for individuals in the population and two analyses for
patients in the population. The dichotomous models for
DDDs and costs for individuals gave similar results, so
we used only the one for DDDs. We generated three dif-
ferent models for each analysis: Model 1 adjusted for
multi-morbidity, Model 2 adjusted for multi-morbidity
and gender, Model 3 adjusted for multi-morbidity, gender
and age.
Results
Study population
A majority (66%) of the study population used licit pre-
scription drugs during 2006 and a significantly higher
proportion of females used licit prescription drugs
(Table 1). In the age group 70 years or older and in RUB
2 or higher 80% or more used licit prescription drugs.
Among patients using licit prescription drugs 60% were
50 years or older. A lower proportion of those with
higher SES used licit prescription drugs (Table 1).
Gender
After adjustment of multi-morbidity male individuals
had half the odds of using licit prescription drugs com-
pared to females (Table 2 OR 0.41 (95% CI 0.40- 0.42)).
However, male patients had decreased rates of DDDs
(IRR 0.97 (95% CI 0.96- 0.98)) and increased rates of
costs (IRR 1.14 (95% CI 1.13-1.15)) compared to female
patients (Table 3).
Age
Age increased the odds of using licit prescription drugs
and the oldest individuals in the population (>80 years)
had the highest odds of licit prescription drug use
(Table 2). Age increased the rate of both DDDs and
costs for patients (Table 3).
Socioeconomics
The highest educational level in individuals decreased the
odds of licit prescription drug use by 11%. For individuals
the lowest income level had the lowest odds of licit pre-
scription drug use and the second lowest level of income
had the highest odds of licit prescription drug use,
increased by 16% (Table 2). The highest educational level
of patients was associated with a reduced rate of DDDs of
21% and a reduced rate of costs of 8% (Table 3). The
Table 1 Characteristics of the population’s licit
prescription drug use
Licit prescription drug use in total population
Variables Yes No
N(%) N(%)
All 205827 (66) 108150 (35)
Gender Female 121682 (77) 37021 (23)
Male 84145 (54) 71129 (46)
Age 20-29 23916 (51) 23289 (49)
30-39 27666 (53) 24568 (47)
40-49 30419 (56) 24293 (44)
50-59 34946 (65) 19045 (35)
60-69 36745 (73) 11376 (34)
70-79 27643 (87) 4038 (13)
80- 24492 (94) 1541 (6)
Multi-morbidity
level 0 26822 (26) 75013 (74)
1 30364 (69) 13491 (31)
2 51674 (80) 12913 (20)
3 82988 (93) 6595 (7)
4 10775 (99) 126 (1)
5 3204 (99.6) 12 (0.4)
Educational level* 1 15377 (73) 5732 (27)
up to 60–69years 2 16292 (62) 10003 (38)
3 74886 (60) 50695 (40)
4 45296 (56) 35001 (44)
Income level** 1 55260 (70) 23185 (30)
2 59030 (75) 19415 (25)
3 48816 (62) 29630 (38)
4 42720 (55) 35724 (45)
*Missing 2981, **Missing 197.
N– Number of observations.
Table 2 Odds ratio of licit prescription drug use in the
population
Variables OR (95%) P-value
Gender1
Female 1
Male 0.41 (0.40-0.42) 0.000
Age (years)2
20-29 1
30-39 1.04 (1.001.08) 0.027
40-49 1.26 (1.221.08) 0.000
50-59 1.85 (1.781.88) 0.000
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DDDs by 27% and the rate of costs by 29% (Table 3).60-69 3.03 (2.943.03) 0.000
70-79 4.76 (4.545.00) 0.000
80 9.09 (8.3310.00) 0.000
Educational level3 up to 60–69 years
1 1
2 0.97 (0.92-1.02)* 0.261
3 0.94 (0.90-0.99) 0.014
4 0.89 (0.85-0.93) 0.000
Income level3
1
2 1.16 (1.14-1.20) 0.000
3 1.06 (1.03-1.09) 0.000
4 1.05 (1.02-1.08) 0.001
1Adjusted for multi-morbidity, 2Adjusted for multi-morbidity and gender,
3Adjusted for multimorbidity, gender and age.
OR – odds ratio, 95% – confidence interval, DDDs – Defined Daily Doses.Discussion
Gender
The finding that females have higher odds of licit pre-
scription drug use than males in the population although
males represent higher costs has previously been shown
[2,29]. What we have shown here is that the difference
between female and male individuals in the population
and among patients remains after adjustment for multi-
morbidity. One hypothesis is that males and females
have different healthcare seeking behaviour. Statistics
from USA indicate that females seek more preventive
healthcare than males, but emergency treatment at the
same rate [30]. This could indicate that men seek health
care later than females and could partly explain why
males have lower odds of licit prescription drug usedespite the same multi-morbidity [31]. However, re-
search in this area has not found any clear evidence to
support that hypothesis. It has also been discussed that
females and males have different ways of describing
symptoms and therefore have different odds of licit pre-
scription drug use [32]. The differences in prevalence of
disease between the genders have been discussed before
[8]. For example, males have more licit prescription drug
treatment for cardiovascular disease while females have
more licit prescription drug treatment for anxiety and
depression diagnoses [29]. How this difference in diag-
nosis prevalence affects licit prescription drug use and
costs is not examined here but we cannot exclude the
possibility that it may affect our results. Even though it
has not been examined in this study we cannot exclude
that the licit prescription drugs are being prescribed in a
biased way related to doctors’ characteristics.
Age
Despite the same multi-morbidity level age increased
the odds of licit prescription drug use in individuals
and rate of use in patients. Among elderly one can
talk about the “prescribing cascade”. It is described as
starting as an adverse drug reaction that is misinter-
preted as a new medical condition. A new drug is then
Table 3 The incidence rate ratio of using licit prescription drugs and costs for licit prescription drug use among
patients
Variables DDDs Costs
IRR (95%) P-value IRR (95%) P-value
Gender1
Female 1 1
Male 0.97 (0.96–0.98) 0.000 1.14 (1.13–1.15) 0.000
Age (years)2
20–29 1 1
30–39 1.07 (1.05–1.09) 0.000 1.07 (1.05–1.10) 0.000
40–49 1.50 (1.47–1.53) 0.000 1.42 (1.39–1.46) 0.000
50–59 2.18 (2.14–2.22) 0.000 1.63 (1.59–1.67) 0.000
60–69 2.97 (2.91–3.03) 0.000 1.88 (1.84–1.92) 0.000
70–79 3.68 (3.60–3.76) 0.000 1.95 (1.90–1.99) 0.000
80 4.50 (4.40–4.60) 0.000 1.95 (1.91–2.00) 0.000
Educational level3
up to 60–69 years 1 1 1
2 0.99 (0.96–1.02)* 0.341 1.05 (1.02–1.09) 0.002
3 0.85 (0.83–0.87) 0.000 0.96 (0.93–0.98) 0.002
4 0.78 (0.76–0.80) 0.000 0.92 (0.89–0.94) 0.000
Income level3
1 1 1
2 1.00 (0.99–1.02)* 0.657 0.97 (0.96–0.99) 0.001
3 0.81 (0.80–0.82) 0.000 0.83 (0.82–0.85) 0.000
4 0.73 (0.71–0.74) 0.000 0.71 (0.70–0.72) 0.000
IRR – incidence rate ratio, 95% – confidence interval, DDDs – defined daily doses
1Adjusted for multi-morbidity, 2Adjusted for multi-morbidity and gender, 3Adjusted for multimorbidity,
gender and age.
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additional adverse effects relating to this potentially
unnecessary treatment [1].
Another hypothesis as to why elderly, despite same
multi-morbidity, have higher odds of licit prescription
drug use is that the evaluation of the licit prescription
drug treatment may have been neglected.
Different treatment ways for different age groups can
affect the odds of licit prescription drug use in the popu-
lation and rate of use in patients. Younger individuals
are probably more likely to be recommended lifestyle
changes as a first point of action before licit prescription
drug treatment to treat for example hypertension. The
duration of a disease in a patient also influences the
DDDs for the same disease. Hypertension may again be
used as a good example since physiological changes
increases the blood pressure the older the individuals
get. It is worrying that elderly, who are the most sensi-
tive to drugs, have the highest use of licit prescription
drugs. All clinicians need to get better at reviewing licit
prescription drug treatment in the elderly and phase out
treatment that no longer has an indication.Socioeconomics
After adjustment for multi-morbidity level, gender and
age individuals in the lowest income level had the lowest
odds of licit prescription drug use in the population,
while the second lowest income level had the highest
odds of licit prescription drug use. We had expected the
lowest income level to have the highest odds of licit pre-
scription drug use. Our interpretation to the result is
that it could depend on poor economy in the lowest in-
come level, preventing these individuals from collecting
their licit prescription drugs. This is interesting since
Sweden has a high cost threshold system for licit pre-
scription drugs [21]. Provided that the licit prescription
drug is granted reimbursement status, the individual
does not pay more than SEK 1800 (~180 EUR) per 12-
month period for licit prescription drugs. The finding
that the lowest income level has the lowest odds of licit
prescription drug use may indicate that there are indivi-
duals in the population who despite a pharmaceutical
benefit system do not collect their prescribed drugs. This
theory is supported by the fact that there is no statistical
significant difference in the odds of licit prescription
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education (Table 2).
Former studies have shown differences in healthcare
seeking behaviour with higher consultation rates among
individuals in lower social classes [33]. Even though it is
not studied here, it is possible that higher rates of
healthcare seeking increase the licit drug prescribing.
Individuals with low education have proved to a lesser
extent to act on information concerning health risks
such as smoking [34]. If this fact also affects the capacity
to act on doctors’ recommendations of lifestyle changes
it may lead to increased licit drug prescribing.
Limitations
Our study includes the total population of Östergötland
county, which is representative of the rest of Sweden
[27].
Since individuals 70 years or older was excluded when
analysing educational level it was impossible to adjust
for both income and education consecutively and there-
fore we analysed these variables separately. The missing
data in the rest of the variables were minor and did not
affect the results.
ACG Case-Mix uses diagnoses to calculate multi-
morbidity and is therefore dependent on the quality of
registration of diagnoses [16]. The recording of diagnoses
in this study is not validated. However, a prior study in
Sweden has shown that 75% of the population had at
least one diagnosis-registered encounter at a GP during a
three-year period [35]. During 2006 Östergötland did not
use ACG Case-Mix for reimbursement and therefore the
risk of up coding is unlikely. It is more likely that there is
an under-registration [36].We were not able to assess
illicit drug use and these drugs are not included in this
study. Data from Medical Products Agency indicates that
11% of the Swedish population has bought prescription
drugs from non-approved pharmacies during 2011[37].
In this study we have data on licit prescription drugs
that were collected from the pharmacies but we do not
have information on to what extent the patients actually
used them.
Future studies
This study has provided an important insight into which
variables influence licit prescription drug use. Multi-
morbidity is clearly not the only factor affecting licit pre-
scription drug use. There are evident differences between
gender, age and socioeconomic status. Future studies
should focus on what these differences depend on.
Conclusion
This study shows that there is a great variability in licit
prescription drug use with regard to gender, age and
socioeconomic status that cannot be explained bydifferent levels of multi-morbidity. On the contrary, the
studied factors - gender, age and socioeconomic status -
seem to have a high impact on licit prescription drug
use. This clearly illustrates that there are more variables
than multi-morbidity influencing a patient’s licit pre-
scription drug use. It is of utmost importance that politi-
cians, officials and doctors are aware of that fact.
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